

## SUPPLEMENTARY TABLES

**Table S1:** FMD and NMD at baseline and 16 week visits

Parameter	Placebo (n=59)	Cholecalciferol (n=58)	P value
<b>At Baseline</b>			
FMD (%)	7.85±2.35	7.65±2.25	0.65
NMD (%)	11.43±4.07	11.20±4.12	0.59
Shear stress (m/sec)	189.27±84.37	186.44±74.14	0.85
<b>At 16 weeks</b>			
FMD (%)	7.78±2.90	13.07±3.96	<0.001
NMD (%)	10.69±3.44	13.31±3.97	<0.001
Shear stress (m/sec)	180.50±71.38	184.00±74.94	0.80
Proportional increase in FMD (%) <sup>a</sup>	2.78 (-16.50,13.58)	62.95 (34.96- 96.65)	<0.001
Proportional increase in NMD (%) <sup>a</sup>	-4.38 (-31.61, 12.38)	12.40 (-5.54, 51.39)	<0.001

Abbreviations: FMD, endothelium dependent flow mediated dilatation; NMD, endothelium independent nitroglycerine mediated dilatation.


Data presented as mean± standard deviation and median (25<sup>th</sup>, 75<sup>th</sup> percentile).

<sup>a</sup>Compared using Mann-Whitney U test

**Table S2:** Adverse events recorded during the study (number of subjects)

<b>Adverse events</b>	<b>Placebo</b>	<b>Cholecalciferol</b>
<b>Bodyaches</b>	4	1
<b>Dyspepsia</b>	1	2
<b>Mild lower limb edema</b>	1	2
<b>Upper respiratory tract infection</b>	1	2
<b>Urinary tract infection</b>	0	1
<b>Dengue</b>	1	0
<b>Lower limb cellulitis</b>	1	0
<b>Excessive hair growth</b>	0	1
<b>Hypercalcemia (serum calcium &gt;10.5 mg/dl)</b>	1	0

**Supplementary figure S1: Comparison between selected parameters at 16 weeks and change over 16 weeks in either group**



PTH: parathyroid hormone